High-dose therapy for indolent lymphoma

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 2, 2002, Pages 225-239

  Mounier, Nicolas ^a   Socié, Gérard ^a   Gisselbrecht, Christian ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Antineoplastic agents; Combined modality therapy; Dose response relationship; Drug; Follicular indolent; Hematopoietic stem cell transplantation; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; MONOCLONAL ANTIBODY;

ALLOGRAFT; AUTOGRAFT; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; HUMAN; LYMPHOMA; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; RELAPSE; REMISSION; REVIEW; TIME;

ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BONE MARROW PURGING; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036168457     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00159-7     Document Type: Review

References (98)

1. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group
2. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1977
3. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes
4. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients
5. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon-alfa: a randomized study from the Groupe d'etude des Lymphomes Folliculaires. Groupe d'étude des Lymphomes de l'Adulte
6. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'etude des Lymphomes de l'Adulte
7. Low-grade non-Hodgkin's lymphoma: development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND)
8. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma
9. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
10. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
11. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte
12. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group
13. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma
14. Therapy related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
15. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
16. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
17. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
18. The clinical significance of molecular response in indolent follicular lymphomas
19. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years
20. Prognostic factors in follicular lymphomas
21. Low-grade follicular lymphoma: multivariate analysis of prognostic factors in 484 patients-a study of the Groupe d'etude des Lymphomes de l'Adulte
22. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model
23. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases
24. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party
25. Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party
26. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma
27. A predictive model for aggressive non-Hodgkin's lymphoma
28. A multi-states regression analysis for competing events in follicular lymphoma patients included in the GELF86 trial
29. Patterns of survival in patients with recurrent follicular lymphoma: a 20 year study from a single center
30. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation
31. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma
32. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma
33. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
34. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma
35. Long-term survival after histologic transformation of low-grade follicular lymphoma
36. Incidence of histological transformation in follicular lymphoma patients included in the prospective GELF86 protocol
37. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies
38. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre
39. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
40. High-dose therapy and auto-grafting for follicular lymphoma low-grade lymphoma in first remission: the Stanford experience
41. Value of autologous bone marrow transplantation (ABMT) in 42 patients with follicular lymphomas responsive to conventional chemotherapy: a 'France Autogreffe' study
42. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
43. Myeloablative radiochemotherapy followed by blood-stem cell-transplantation significantly prolongs the disease-free interval in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: results of a prospective randomized comparison by the German Low-grade Lymphoma Study Group (GLSG)
44. Long-term results of low dose total body irradiation for advanced non-Hodgkin's lymphoma
45. Results of total body irradiation in the treatment of advanced non-Hodgkin's lymphomas
46. Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin's lymphoma: results of a pilot study
47. Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: the European Bone Marrow Transplant Group experience. EBMT Working Party for Lymphoma
48. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies
49. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study
50. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors
51. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma
52. All advanced stage non-Hodgkin's lymphomas with polymerase chain reaction amplifiable breakpoint of BCL2 have residual cells containing the BCL2 rearrangement at evaluation and after treatment
53. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
54. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique
55. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells
56. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
57. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma
58. The CUP trial: a randomized study analyzing the efficacy of high-dose therapy and purging in low-grade non-Hodgkin's lymphoma
59. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
60. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma
61. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation-results of a retrospective analysis on 120 patients autografted in a single institution
62. Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment
63. Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience
64. + peripheral blood stem cells: retained engraftment capability and reduced tumour cell content
65. Rapid and effective depletion of B cells using CD19 and CD20 monoclonal antibodies coupled to high density microparticles (HDM)
66. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma
67. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management
68. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology
69. Allogeneic bone marrow transplantation for low-grade lymphoma
70. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma
71. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up
72. T-cell depletion of HLA-identical transplants in leukemia
73. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma
74. Allogeneic bone marrow transplantation for refractory and recurrent follicular lymphoma: a case-matched analysis with autologous transplantation from the French Bone Marrow Transplant Group registry data
75. Allogeneic or autologous bone marrow/peripheral stem cell transplantation for follicular lymphoma: a cohort analysis from the Fred Hutchinson Cancer Research Center
76. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
77. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
78. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy
79. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies
80. Transplant-lite using fludarabine-cyclophosphamide and allogeneic stem cell transplant for low grade lymphoma
81. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
82. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma
83. Myelodysplasia after autotransplantation
84. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma
85. Monoclonal antibody-based therapies for hematologic malignancies
86. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
87. Progressive intermediate grade non-Hodgkin's lymphoma after high dose therapy and autologous peripheral stem cell transplantation (PSCT) has a high response rate to rituximab
88. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients
89. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
90. Radioimmunotherapy of non-Hodgkin's lymphomas
91. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse
92. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas
93. Interleukin-12 immunotherapy after autologous stem cell transplantation for cancer
94. Interferon alpha2b versus no treatment after intensive therapy and autologous stem cell transplantation for relapsing lymphoma. Preliminary results of an international randomized study on 199 patients
95. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
96. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
97. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity